@Gan_Gans, Thank you for the research findings. I noticed that the invention claim on the one you referenced excludes osteoarthritis as part of the coverage of the invention. Did you find others that cover specifically for osteoarthritis (in humans maybe)? I would be keen to find a reference to the list of patents they hold if you have it handy. Thanks.
REF:
The invention claimed is:1. A method for the treatment of bone marrow edema in a mammal not suffering from osteoarthritis, comprising administering intra-articularly or peri-articularly from about 1 mg/kg to about 2 mg/kg per dose of a polysulfated polysaccharide selected from the group consisting of pentosan polysulfate, the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), and the calcium salt of pentosan polysulfate (CaPPS) to a mammal in need of such treatment.
- Forums
- ASX - By Stock
- PAR
- Paradigm Ip Patents/ Trademarks
Paradigm Ip Patents/ Trademarks, page-23
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M |
Open | High | Low | Value | Volume |
25.5¢ | 25.5¢ | 25.0¢ | $7.539K | 29.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4741 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.5¢ | 52986 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 8132 | 0.250 |
4 | 39101 | 0.245 |
7 | 118434 | 0.240 |
7 | 65556 | 0.235 |
6 | 208906 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 50086 | 14 |
0.260 | 6790 | 2 |
0.265 | 5666 | 2 |
0.270 | 21800 | 3 |
0.275 | 15436 | 3 |
Last trade - 12.04pm 28/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
Previous Video
Next Video
SPONSORED BY The Market Online